Aduro Biotech Announces Upcoming Data Presentations at the Keystone Symposia on Cancer Immunology and Immunotherapy Conferenc...
March 02 2017 - 4:05PM
Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with
three distinct immunotherapy technologies, today announced data
presentations relating to its technology platforms to be given at
the Keystone Symposia on Cancer Immunology and Immunotherapy
Conference: Taking a Place in Mainstream taking place in Whistler,
B.C., Canada, March 19 through 23, 2017.
|
|
|
|
Poster 1061: |
|
|
Administration of the
synthetic STING agonist ADU-S100 leads to durable anti-tumor
immunity via promoting T-cell responsesPoster Session:
1Date/Time: Monday, March 20, 7:30 p.m. to 10:00 p.m. PT |
|
|
|
|
Poster 2038: |
|
|
Efficacy of pLADD, a
personalized immunotherapy strategy targeting tumor-specific
neoantigens using live attenuated Listeria monocytogenes Poster
Session: 2 Date/Time: Tuesday, March 21, 2017, 7:30 p.m. to
10:00 p.m. PT |
|
|
|
|
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
mesothelioma, ovarian, lung and prostate cancers. Additionally, a
personalized form of LADD, or pLADD, is being developed utilizing
tumor neoantigens that are specific to an individual patient’s
tumor. Aduro's STING Pathway Activator platform is designed to
activate the STING receptor in immune cells, resulting in a potent
tumor-specific immune response. ADU-S100 is the first STING Pathway
Activator compound to enter the clinic and is currently being
evaluated in a Phase 1 study in patients with cutaneously
accessible metastatic solid tumors or lymphomas. Aduro’s B-select
monoclonal antibody platform includes a number of immune modulating
assets in research and preclinical development. Aduro is
collaborating with leading global pharmaceutical companies to
expand its products and technology platforms. For more information,
please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, our technology platforms, plans,
and the potential for eventual regulatory approval of our product
candidates. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “seek”, “expect” or the
negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, our history of net operating losses
and uncertainty regarding our ability to achieve profitability, our
ability to develop and commercialize our product candidates, our
ability to use and expand our technology platforms to build a
pipeline of product candidates, our ability to obtain and maintain
regulatory approval of our product candidates, our inability to
operate in a competitive industry and compete successfully against
competitors that have greater resources than we do, our reliance on
third parties, and our ability to obtain and adequately protect
intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our annual report on Form 10-K for the
year ended December 31, 2016, which is on file with the Securities
and Exchange Commission. Any forward-looking statements that we
make in this press release speak only as of the date of this press
release. We assume no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Susan Lehner
510 809 2137
press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024